Aclarion, Inc. (Nasdaq: ACON) is a Broomfield, Colorado-based medical-technology company commercializing Nociscan, a software-as-a-service diagnostic that uses magnetic resonance spectroscopy (MRS) - a chemical-signal imaging technique that distinguishes pain-related biomarkers from structural noise on standard MRI scans - combined with a cloud-based artificial-intelligence classifier to help physicians identify which spinal discs are the source of chronic low-back pain. In the three months ended June 30, 2026, Aclarion recognized $25,208 of revenue from the delivery of Nociscan reports - up 30.5% from the $19,319 reported a year earlier - and turned in a net loss of $2,747,551, or $(1.12) per share, on a weighted-average share count of 2,462,250. The cash position of $16,310,462 (including $25,000 of restricted cash) at quarter-end, plus $10.4 million of gross proceeds the company raised in January 2026 through a registered-direct offering of 200,000 common shares and 1,800,000 pre-funded warrants at $5.18 per unit, gives management a stated runway that extends into the second half of 2027 on the current operating cadence. At a closing market price of $2.88 per share on June 30, 2026 (as disclosed in the warrant-liability footnote), the company carries a market capitalization in the $7-9 million range - a single-digit valuation against $16.3 million of cash, which is the load-bearing observation: the equity is trading at roughly half of net cash, with the operating business and IP portfolio assigned negative enterprise value by the market. The falsification clock for the bull case is Nociscan 3.0 commercialization milestones and the run-rate revenue trajectory; the falsification clock for the bear case is whether the next financing window opens before the H2 2027 runway exhausts and at what dilution.